Stephen T Gordon

Array ( [id] => 18879163 [patent_doc_number] => 20240002532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING [patent_app_type] => utility [patent_app_number] => 18/346130 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 178 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18346130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18567119 [patent_doc_number] => 20230257448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => BISPECIFIC SARS-COV-2 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/149593 [patent_app_country] => US [patent_app_date] => 2023-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18149593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484965 [patent_doc_number] => 20230212280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => IL-23 Specific Antibodies for the Treatment of Systemic Sclerosis [patent_app_type] => utility [patent_app_number] => 18/082695 [patent_app_country] => US [patent_app_date] => 2022-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18082695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468918 [patent_doc_number] => 20230203202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => PROTEINS BINDING NKG2D, CD16 AND 5T4 [patent_app_type] => utility [patent_app_number] => 18/062453 [patent_app_country] => US [patent_app_date] => 2022-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -206 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18376005 [patent_doc_number] => 20230151087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody [patent_app_type] => utility [patent_app_number] => 17/986374 [patent_app_country] => US [patent_app_date] => 2022-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51051 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17986374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436064 [patent_doc_number] => 20230183358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => ANTIBODY MOLECULES AND CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/053955 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19457730 [patent_doc_number] => 12098210 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies [patent_app_type] => utility [patent_app_number] => 18/052174 [patent_app_country] => US [patent_app_date] => 2022-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 36743 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 295 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436021 [patent_doc_number] => 20230183315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => Regulatory T Cells Expressing Chimeric Antigen Receptors and Uses in Synucleinopathies [patent_app_type] => utility [patent_app_number] => 17/938258 [patent_app_country] => US [patent_app_date] => 2022-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522981 [patent_doc_number] => 20230233633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => METHOD FOR TREATING PD-L1 EXPRESSING CANCER [patent_app_type] => utility [patent_app_number] => 17/937850 [patent_app_country] => US [patent_app_date] => 2022-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597285 [patent_doc_number] => 20230272080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS [patent_app_type] => utility [patent_app_number] => 17/935154 [patent_app_country] => US [patent_app_date] => 2022-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30624 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18307463 [patent_doc_number] => 20230111363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => HUMAN MONOCARBOXYLATE TRANSPORTER 1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/932039 [patent_app_country] => US [patent_app_date] => 2022-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18297618 [patent_doc_number] => 20230107304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => METHODS OF TREATING CANCER AND TUMOR-RELATED WEIGHT LOSS AND CACHEXIA [patent_app_type] => utility [patent_app_number] => 17/929518 [patent_app_country] => US [patent_app_date] => 2022-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18351827 [patent_doc_number] => 20230139938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 Inhibition [patent_app_type] => utility [patent_app_number] => 17/870593 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17870593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18058001 [patent_doc_number] => 20220389087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => GENERATION OF A NEW SITE-SPECIFIC MONOCLONAL ANTIBODY FOR TAU PROTEIN AND ITS USE AS A TOOL IN SPECIFIC BIOMARKERS FOR EARLY DETECTION OF NEURODEGENERATIVE DISEASES AND PATHOLOGIES [patent_app_type] => utility [patent_app_number] => 17/825511 [patent_app_country] => US [patent_app_date] => 2022-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17825511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675533 [patent_doc_number] => 20230313140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => METHOD FOR PREPARING T CELLS FOR ADOPTIVE T CELL THERAPY [patent_app_type] => utility [patent_app_number] => 17/712787 [patent_app_country] => US [patent_app_date] => 2022-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13249 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17712787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597274 [patent_doc_number] => 20230272069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof [patent_app_type] => utility [patent_app_number] => 17/681855 [patent_app_country] => US [patent_app_date] => 2022-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17868496 [patent_doc_number] => 20220291232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS [patent_app_type] => utility [patent_app_number] => 17/555636 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17555636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561695 [patent_doc_number] => 20220125844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => OPIOID ANTAGONISTS FOR USE IN PATIENTS USING CHIMERIC ANTIGEN RECEPTOR T AND NATURAL KILLER (NK) CELL THERAPY [patent_app_type] => utility [patent_app_number] => 17/508673 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17508673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19181064 [patent_doc_number] => 11987646 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-21 [patent_title] => Immunomodulatory peptides [patent_app_type] => utility [patent_app_number] => 17/497069 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 7366 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17497069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368293 [patent_doc_number] => 20220023345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection [patent_app_type] => utility [patent_app_number] => 17/377922 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 209 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377922 [rel_patent_id] =>[rel_patent_doc_number] =>)